Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

September 30, 2022

https://www.globenewswire.com/news-release/2022/09/30/2526322/0/en/Sensei-Biotherapeutics-Presents-Preclinical-Data-for-SNS-101-a-Conditionally-Active-VISTA-blocking-Antibody-at-the-Sixth-Annual-CRI-ENCI-AACR-International-Cancer-Immunotherapy-Con.html

– SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a pH-independent VISTA antibody

Read more at globenewswire.com

Related news for (SNSE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.